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Abstract Opsoclonus–myoclonus syndrome (OMS) is a
rare acquired movement disorder occurring in all age
groups, predominantly in infants. Although the exact
pathogenesis is still undefined, there is strong evidence
for a paraneoplastic or parainfectious immune process
resulting in central nervous system dysfunction. Mycoplas-
ma pneumoniae has been implicated in a number of
immune-mediated neurologic diseases [28]. However, the
association of M. pneumoniae and opsoclonus–myoclonus–
ataxia syndrome is not well established so far. We present
three cases with opsoclonus–myoclonus–ataxia syndrome
in adolescents following an infection with M. pneumoniae.
Monophasic disease course and full recovery correspond to
the favorable prognosis known from parainfectious cases in
young adults. This should affect therapeutic consideration.
OMS should be added to the spectrum of M. pneumoniae-
associated neurologic complications. Nevertheless, neuro-
blastoma has to be ruled out in all cases of OMS.
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Introduction
Opsoclonus–myoclonus syndrome (OMS), also known as
“dancing eye syndrome”, is a rare neurological disorder,
characterized by the combination of involuntary, irregular,
multidirectional but conjugated eye movements, myoclonus
that predominantly involves neck and trunk, and signs of
cerebellar ataxia, especially the inability to stand and walk.
While the clinical presentation is quite typical, the exact
immunopathogenesis, neuroanatomical localization, and path-
ophysiology are still uncertain [26, 27]. First described in
children as “myoclonic encephalopathy of infancy” by
Kinsbourne in 1962 [9], it occurs both in children and adults
as a paraneoplastic or parainfectious process in association
with a variety of neoplastic and infectious diseases. Among
the pediatric population, the syndrome is best known between
six and 36 months of age and neuroblastomas can be
identified in up to 50% of these cases; in contrast, it is rare
in older children and adolescents [21]. In adults, OMS is
related to different types of malignant tumors [1, 2], but occurs
more frequently in association with systemic infection [23].
Although this is known for many different infectious diseases,
there is only one recently published case of a four-year-old girl
describing the association with Mycoplasma pneumoniae (M.
pneumoniae) infection [4]. We present three adolescents with
OMS following an infection with M. pneumoniae.
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Case report
Case 1 A 10-year-old previously healthy girl was sent to
our hospital because of uncontrolled eye movements and
tremor of the whole body starting 3 days before. History
revealed pneumonia 2 weeks earlier. On admission, the girl
was afebrile with normal vital signs, but ill appearing and
irritable. The neurological examination showed disabling,
intermittent, multidirectional, chaotic eye movements and
myoclonia of the proximal extremities. No other abnormal-
ities could be found. On the following days, gait impair-
ment and dysmetria occurred as signs of cerebellar ataxia.
The girl needed assistance for walking and preferred to
keep her eyes closed to reduce oscillopsia. The complete
laboratory workup only showed a slight elevation of C-
reactive protein (34 mg/l). A lumbar puncture yielded clear,
colorless cerebrospinal fluid (CSF) with elevated leuko-
cytes (58/mm3, exclusively mononuclear cell type); glucose
and protein concentrations were 5.86 mmol/l and 0.92 g/l,
respectively. The neopterin level was markedly increased
(77.5 nmol/l); other biogenic amines, folates, and pterins
were within the normal range. Further CSF investigation
demonstrated intrathecal antibody production as well as
elevated protein and albumin levels. There was no
serological evidence for acute or previous infection with
Epstein–Barr virus (EBV) or Borrelia burgdorferi, and CSF
analysis was negative for bacterial and enteroviral infection.
However, M. pneumoniae-polymerase chain reaction (PCR)
was positive in nasopharyngeal secretions and IgM anti-
bodies were elevated (Table 1). Cranial magnetic resonance
imaging (MRI) did not reveal pathologic alterations in the
neurocranium, in particular, there were no signs of
cerebellar or brain stem inflammation. With normal urine
catecholamines, normal abdominal sonography, and chest
X-ray, there was no evidence for a paraneoplastic etiology
of OMS.
On day 4, the girl was started on methylprednisolone
at a dosage of 3.2 mg/kg/day. The symptoms of OMS
slowly improved, but she developed psychotic adverse
effects of high-dose steroid therapy. Therefore, the
methylprednisolone dosage was reduced and additional
therapy with intravenous immunoglobulins was started.
The girl was discharged home after 18 days with a
persistent slight opsoclonus, myoclonus, and atactic
disorder. One month later, apart from a discrete intention
tremor, she showed a full recovery without any overt
cognitive impairment. The therapy with oral prednisolone
was weaned over 10 months. No relapses occurred for a
total follow-up of 30 months.
Case 2 A 14-year-old previously healthy girl was referred
to our hospital because of a strange movement disorder of
her eyes accompanied by unsteadiness, dizziness, nausea,
and reduced general condition. Four weeks before admis-
sion she suffered from a febrile respiratory disease (sore
throat, severe cough). Abnormal findings in the physical
examination were diffuse action tremor, myoclonias of the
trunk, neck and proximal extremities, signs of cerebellar
ataxia with astasia and abasia, and the characteristic finding of
opsoclonus. Laboratory tests were normal except for a slight
mononuclear pleocytosis (15/mm3), an increased protein
level (0.51 g/l) as well as positive oligoclonal bands in the
clear CSF. CSF level for 5-hydroxyindoleacetic acid was
decreased (54 nmol/l); level of homovanillic acid was in the
lower reference range (168 nmol/l). Microbiologic inves-
tigations could exclude acute infection by EBV, adenovirus,
enterovirus, tick-borne encephalitis virus, Borrelia burgdor-
feri, and group A streptococci. However, complement
binding antibody test for M. pneumoniae was strongly
positive with 1:1,920; IgM antibodies were elevated
(Table 1). There was no elevation of catecholamines and
their metabolites in a 24-hour urine sample and chest X-ray,
sonography of the abdomen as well as cranial MRI were
normal.
After an initial deterioration of neurological signs and
symptoms, there was marked improvement following ther-
apy with high-dose methylprednisolone (8.5 mg/kg/day).
The girl was discharged on day 10 with a discreet residual
opsoclonus and unsteadiness. Treatment with oral prednis-
olone was continued and weaned over 4 months. While
developing slight and transient signs of hypercortisolism,
recovery from OMS was achieved after 4 weeks. A slight
hand tremor disappeared during the following months, no
relapses occurred during 15 months follow-up.
Case 3 A 14-year-old boy with an uneventful past medical
history presented with gait impairment, dizziness, and
involuntary chaotic eye movements. He suffered from a
febrile infection with sore throat and cough 2 weeks earlier.
On admission, he was afebrile and the physical examination
revealed opsoclonus accompanied by a truncal ataxia
making standing and walking difficult. No other clinical
abnormalities and no pathologic results in the standard
laboratory workup could be found. The clear and colorless
CSF showed a minimal mononuclear pleocytosis (5/mm3),
positive oligoclonal bands, but normal glucose and protein
levels. CSF level of neopterin was clearly increased
(46.6 nmol/l); the level of 5-hydroxyindoleacetic acid was
decreased (56 nmol/l). Results of urine catecholamines were
normal. In microbiological investigations, the complement
binding antibody test for M. pneumoniae was strongly
positive with 1; 1,280; IgM serology was positive (Table 1).
Acute infection with EBV, enterovirus, B. burgdorferi, and
group A streptococci was ruled out. Abdominal sonography
and cranial MRI were normal, while chest X-ray showed an
atypical pneumonia.
442 Eur J Pediatr (2010) 169:441–445
T
ab
le
1
S
um
m
ar
y
of
th
re
e
ca
se
s
C
as
e
no
.
A
ge
in
ye
ar
s
S
ex
S
ig
ns
an
d
sy
m
pt
om
s
P
ro
dr
om
al
ill
ne
ss
D
ia
gn
os
tic
im
ag
in
g
(b
ra
in
M
R
I,
ch
es
t
X
-r
ay
,
ab
do
m
en
so
no
gr
ap
hy
)
U
ri
ne
ca
te
ch
ol
am
in
es
/
m
et
ab
ol
ite
s
C
S
F
M
ic
ro
bi
ol
og
ic
al
ev
al
ua
tio
n
In
te
rv
al
st
ar
tin
g
tr
ea
tm
en
t
T
he
ra
py
F
ol
lo
w
-u
p
1
10
5/
12
F
O
ps
oc
lo
nu
s,
m
yo
cl
on
us
,
at
ax
ia
,
ir
ri
ta
bi
lit
y
(s
ev
er
e)
P
ne
um
on
ia
2
w
ee
ks
ea
rl
ie
r
N
or
m
al
N
or
m
al
58
ly
m
ph
/m
m
3
pr
ot
ei
n
0.
92
g/
l
ne
op
te
ri
n
↑
ol
ig
oc
lo
na
l
ba
nd
s
po
s.
P
os
iti
ve
M
.
pn
eu
m
on
ia
e-
P
C
R
(n
as
al
se
cr
et
io
ns
)
M
.
pn
eu
m
on
ia
e
Ig
G
32
8
kU
/l
(<
90
)
M
.
pn
eu
m
on
ia
e
Ig
M
31
9
kU
/l
(<
90
)
4
da
ys
M
P
iv
(3
m
g/
kg
/d
)
P
po
10
m
on
th
s
IV
IG
30
m
on
th
s
re
m
is
si
on
w
ith
in
1
m
on
th
tr
em
or
of
ha
nd
s;
no
re
la
ps
es
2
14
2/
3
F
O
ps
oc
lo
nu
s,
m
yo
cl
on
us
,
at
ax
ia
(m
od
er
at
e)
U
pp
er
re
sp
ir
at
or
y
tr
ac
t
ill
ne
ss
an
d
pn
eu
m
on
ia
4
w
ee
ks
ea
rl
ie
r
N
or
m
al
N
or
m
al
15
ly
m
ph
/m
m
3
pr
ot
ei
n
0.
51
g/
l
ol
ig
oc
lo
na
l
ba
nd
s
po
s.
5-
H
IA
A
an
d
H
V
A
↓
M
.
pn
eu
m
on
ia
e
co
m
pl
em
en
t
bi
nd
in
g
an
tib
od
y
te
st
1:
3,
84
0
(1
:1
0)
M
.
pn
eu
m
on
ia
e
Ig
G
25
9
kU
/l
(<
90
)
M
.
pn
eu
m
on
ia
e
Ig
M
25
4
kU
/l
(<
90
)
7
da
ys
M
P
iv
(8
.5
m
g/
kg
/d
)
P
po
4
m
on
th
s
15
m
on
th
s
re
m
is
si
on
w
ith
in
1
m
on
th
;
tr
em
or
of
ha
nd
s;
no
re
la
ps
es
3
14
1/
2
M
O
ps
oc
lo
nu
s,
at
ax
ia
(m
od
er
at
e)
U
pp
er
re
sp
ir
at
or
y
tr
ac
t
ill
ne
ss
3
w
ee
ks
ea
rl
ie
r
N
or
m
al
N
or
m
al
5
ly
m
ph
/m
m
3
pr
ot
ei
n
0.
29
g/
l
ne
op
te
ri
n
↑
ol
ig
oc
lo
na
l
ba
nd
s
po
s.
5-
H
IA
A
↓
M
.
pn
eu
m
on
ia
e
co
m
pl
em
en
t
bi
nd
in
g
an
tib
od
y
te
st
1:
1,
28
0
(1
:1
0)
M
.
pn
eu
m
on
ia
e
Ig
G
11
2
kU
/l
(<
90
)
M
.
pn
eu
m
on
ia
e
Ig
M
14
8
kU
/l
(<
90
)
4
da
ys
M
P
iv
(1
0
m
g/
kg
/d
)
P
po
3
w
ee
ks
10
m
on
th
s
re
m
is
si
on
w
ith
in
2
w
ee
ks
;
no
re
la
ps
es
M
m
al
e,
F
fe
m
al
e,
M
R
I
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g,
C
SF
ce
re
br
os
pi
na
l
fl
ui
d,
ly
m
ph
ly
m
ph
oc
yt
es
,
5-
H
IA
A
5-
hy
dr
ox
yi
nd
ol
ea
ce
tic
ac
id
,
H
VA
ho
m
ov
an
ill
ic
ac
id
,
M
.
pn
eu
m
on
ia
e
M
yc
op
la
sm
a
pn
eu
m
on
ia
e,
B
.b
ur
gd
or
fe
ri
B
or
re
lia
bu
rg
do
rf
er
i,
E
B
V
E
ps
te
in
–B
ar
r
vi
ru
s,
M
P
M
et
hy
lp
re
dn
is
ol
on
e,
P
P
re
dn
is
ol
on
e,
IV
IG
in
tr
av
en
ou
s
im
m
un
gl
ob
ul
in
s,
iv
in
tr
av
en
ou
s,
po
pe
ro
ra
lly
;
C
S
F
le
ve
ls
of
H
V
A
,
5-
H
IA
A
,
an
d
ne
op
te
ri
n
w
er
e
de
te
rm
in
ed
by
H
P
L
C
(h
ig
h-
pe
rf
or
m
an
ce
liq
ui
d
ch
ro
m
at
og
ra
ph
y)
fo
llo
w
ed
by
el
ec
tr
om
ec
ha
ni
ca
l
de
te
ct
io
n
(D
iv
is
io
ns
of
C
lin
ic
al
C
he
m
is
tr
y
an
d
B
io
ch
em
is
tr
y,
U
ni
ve
rs
ity
C
hi
ld
re
n'
s
H
os
pi
ta
l,
Z
ur
ic
h,
S
w
itz
er
la
nd
)
Eur J Pediatr (2010) 169:441–445 443
A slight clinical improvement was already observed one
day before starting treatment. Under methylprednisolone at
an initial dosage of 10 mg/kg/day, complete remission
without residual cognitive or behavioral impairment was
achieved within 2 weeks. Therapy with oral prednisolone
was weaned over 3 weeks, no relapses occurred for a
follow-up of 10 months.
Discussion
Opsoclonus–myoclonus–ataxia syndrome is a rare acquired
movement disorder affecting both children and adults.
Although the exact etiology as well as the detailed
mechanism of brain injury is still undefined, there is a
broad spectrum of evidence for an immune-mediated
process, suggesting immune system dysregulation of both
humoral and cellular immunity in the context of neoplastic
or infectious diseases [3, 5, 11, 17–20]. The positive effect
of immunomodulatory agents such as corticosteroids or
intravenous immunoglobulin, also used in our cases, gives
further support to the immunopathogenesis of OMS.
CSF in patients with OMS shows pleocytosis with
activated T and B lymphocytes in the CSF [18]. B cell
overrepresentation leads to intrathecal antibody production.
In children with neuroblastoma-related OMS, B cell
expansion is thought to be a biomarker of disease activity.
Therefore, rituximab, a chimeric monoclonal antibody
directed against the CD20 antigen on the surface of mature
B cells, has been successfully used as adjunctive therapy
for OMS [16].
In our three cases, no tumor was detected. However,
there was strong evidence for a previous or ongoing infection
with M. pneumoniae with clearly positive complement-
binding antibody test and markedly elevated IgM serology.
In the first case, a positive PCR of nasopharyngeal
secretions was found. The diagnosis of M. pneumoniae
infection remains a challenge [25]. The complement-
binding antibody test was considered as the standard test
for a long time [6]. Because the complement binding
antibody test lacks of sensitivity and specificity, the
measurement of IgM antibodies with the enzyme-linked
Immunosorbent assay is nowadays successfully used for
diagnosis of M. pneumoniae infection in pediatric patients
[24]. To enhance the sensitivity of testing, PCR analysis is
sometimes added and should also be done in the CSF if the
patient shows neurological symptoms.
This common cause of upper and lower respiratory tract
infections are known to be associated with a wide spectrum
of extrapulmonary manifestations [12, 24]. Besides direct
invasion of affected tissues by M. pneumoniae, immuno-
logic mechanisms are thought to be responsible for the
pathogenesis of those disorders. Neurologic manifestations
are the most common extrapulmonary complications of
M. pneumoniae infections with an overall incidence of
about 0.1% [8, 22]. The use of a macrolide in patients with
a neurologic manifestation consecutive to M. pneumoniae
infection seems to be reasonable even in the absence of
direct central nervous system infection, since macrolides
may have direct anti-inflammatory and immunomodulatory
properties in addition to their antimicrobial activity [27].
Except for a recently published pediatric case report [4],
OMS is not currently listed among the different central
nervous system disorders associated with M. pneumoniae
[7, 12, 15]. The variable CSF abnormalities in M. pneumo-
niae-associated neurological diseases are frequently char-
acterized by an increased white blood cell count
(pleocytosis with lymphocytes predominating), increased
protein, and normal to low glucose level [12]. These
findings correspond with the results of our cases, and there
was additional evidence for intrathecal antibody production
as well as an increased neopterin level, which is known as
an inflammatory marker indicating T cell activation and
cell-mediated immunity [15]. How the autoimmune reac-
tion contributes to the neurologic disorder in OMS remains
unclear, but changes in neurotransmission might play a
role. Our findings of decreased CSF levels of the serotonin
metabolite 5-hydroxyindoleacetic acid and the dopamine
metabolite homovanillic acid as signs of impaired neuro-
transmission correspond with previously reported data [14].
In infants, where OMS is frequently a feature of
neuroblastoma, the course is characterized by multiple
relapses and significant developmental sequelae [10, 13].
Consequently, nearly all children require vigorous and
prolonged immunosuppressive treatment to control neuro-
logic manifestations [15]. Our cases of OMS in adolescents
demonstrate a rather favorable prognosis with a mono-
phasic course and full recovery without neurologic or
cognitive deficits. This is comparable to young adults with
parainfectious OMS and good response to immunotherapy
[2, 27].
Therapeutic differences in duration and dosage of
corticosteroid administration in our cases result from the
initial lack of experience in treating adolescents with OMS
and the variable intensity of disease (severe in case 1,
moderate in case 2 and 3, respectively). In all three cases,
treatment started in the first week of disease manifestation.
This contrasts to the long delay in diagnosis and initiation
of treatment reported by Tate et al. [21] and may have
contributed to the rapid and effective recovery. The clinical
improvement even before treatment observed in case 3
could indicate the possibility of spontaneous regression of
signs and symptoms in this age group. As a consequence,
one can speculate that this subgroup of OMS in adoles-
cence allows a less intense therapeutic procedure without
risking multiple relapses and neurodevelopmental sequelae.
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With this knowledge, adverse effects of immunomodulatory
treatment, especially of prolonged high-dose corticosteroid
administration, could be avoided or at least reduced.
Conclusion
M. pneumoniae is a frequent cause of respiratory tract
infections, and extrapulmonary manifestations are a known
phenomenon. OMS seems to be a previously undescribed
central nervous system complication of M. pneumoniae
infection. Compared to paraneoplastic forms of OMS in
infants, M. pneumoniae associated cases of OMS in
adolescents show a rather benign course without neuro-
developmental long-term sequelae. This affects therapeutic
considerations. OMS should be added to the spectrum of M.
pneumoniae-associated neurologic complications. Never-
theless, neuroblastoma has to be ruled out in all pediatric
cases of OMS.
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